# MHRA Approves Oral Semaglutide: What the Official Decision Means
On 11 June 2026, the Medicines and Healthcare products Regulatory Agency issued a marketing authorisation for oral semaglutide — the tablet formulation of Wegovy — for weight management in adults. It was the culmination of a regulatory review process that began when Novo Nordisk submitted its dossier of clinical evidence to the MHRA, and it made the UK one of the first countries in the world to approve an oral GLP-1 tablet specifically for obesity treatment.
But what does an MHRA approval actually mean? And what does it not mean? Understanding the difference is important for anyone hoping to access oral Wegovy — whether privately or through the NHS.
> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment.
—
## What the MHRA approval means
A marketing authorisation from the MHRA is a legal licence permitting a medicine to be sold and prescribed in the UK. It means the MHRA has reviewed the clinical trial data — in this case the OASIS programme, including OASIS 2 — and concluded that the benefits of the medicine outweigh its risks for the specified patient population.
The specific authorised indication for oral Wegovy covers adults with:
– A BMI of 30 kg/m² or above, or
– A BMI of 27–29.9 kg/m² with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease
This eligibility threshold mirrors the criteria applied to the injectable Wegovy formulation approved in 2023.
The marketing authorisation also sets out the approved dosing schedule: beginning at 1.5mg daily and escalating in stages (1.5mg → 4mg → 9mg → 25mg) over approximately six months. The highest approved dose is 25mg daily.
—
## What the MHRA approval does not mean
An MHRA marketing authorisation is not the same as NHS availability. This distinction is one of the most frequently misunderstood aspects of UK drug approvals.
When the MHRA licences a medicine, it creates the legal framework for prescribing and sale in the UK. What it does not do is require the NHS to fund the medicine, recommend it for use, or allocate a budget for it. That second step — NHS funding — requires a separate recommendation from the National Institute for Health and Care Excellence (NICE), which evaluates whether a medicine represents good value for the NHS in cost-effectiveness terms.
As of June 2026, NICE has not begun an appraisal of oral Wegovy for weight management. The injectable form of Wegovy underwent a NICE appraisal process that took several years. NHS access to injectable Wegovy remains extremely restricted — limited to specialist weight management services for patients with a BMI of 40 or above, with access rationed due to supply constraints. There is no reason to expect a faster path for the tablet formulation.
The practical implication: for the foreseeable future, oral Wegovy is available in the UK via private prescription only.
—
## The evidence base reviewed by the MHRA
The MHRA’s decision was grounded primarily in the OASIS clinical trial programme, conducted by Novo Nordisk. The pivotal trial for the specific tablet formulation at the licensed doses was OASIS 2: a randomised, double-blind, placebo-controlled study in 667 adults over 68 weeks.
Key findings from OASIS 2 that informed the MHRA’s assessment:
– Mean body weight reduction of 15.1% in the semaglutide group versus 2.5% in the placebo group
– 85% of participants achieved at least 5% weight loss
– 50% of participants achieved at least 15% weight loss
– Side effects were predominantly gastrointestinal (nausea, vomiting, diarrhoea) — consistent with the known profile of GLP-1 receptor agonists and generally manageable with gradual dose escalation
The MHRA also considered the body of evidence around semaglutide more broadly, including data from the injectable formulation, which has been used by millions of patients globally since 2021.
—
## The NICE evaluation process: what happens next
For oral Wegovy to become available on the NHS — even in restricted circumstances — it would need to go through NICE’s Technology Appraisal process. This involves:
1. **Scoping:** NICE defines the clinical question and patient population to be evaluated
2. **Evidence submission:** Novo Nordisk submits a dossier of clinical and economic evidence
3. **Independent Evidence Review Group assessment:** an academic group critiques the submission
4. **Appraisal Committee meeting:** NICE’s committee considers the evidence and issues draft guidance
5. **Consultation period:** stakeholders (patients, clinicians, manufacturers) can comment on draft guidance
6. **Final guidance:** NICE issues a binding recommendation to the NHS
This process typically takes 18–24 months from initiation. It has not yet begun for oral Wegovy. Until NICE guidance is published, NHS prescribing of oral Wegovy is not standard practice.
—
## What this means for private patients
For people accessing oral Wegovy through private prescribing services, the MHRA authorisation is the key hurdle — and it has now been cleared. GPhC-registered UK pharmacies and private prescribing platforms are legally permitted to supply oral Wegovy against a valid prescription issued by a registered UK healthcare professional.
Seven providers had opened pre-orders within days of the 11 June approval, with prices starting at £64 per month for the 1.5mg starting dose. Commercial stock is expected to be available for dispatch from most providers in July 2026.
—
## Stay informed as the market develops
The MHRA approval is step one. NICE evaluation, NHS availability, and the arrival of competitor oral GLP-1 medicines — notably Eli Lilly’s orforglipron, expected to seek UK approval in 2027 — will shape the market over the next two years.
CompareWegovyPrices.co.uk tracks every development: provider pricing, regulatory updates, and market changes.
[Compare Wegovy tablet prices from all 7 pre-order providers →](/providers/)
—
*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*
